Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701624 | 1.00 | ASPH (0.34) | ASPHIDO1 | |
| SCHEMBL10260466 | 0.84 | TET2 (0.31) | IDO1 | |
| SCHEMBL30966491 | 0.77 | ALDH1A1 (0.42) | ASPH | |
| SCHEMBL27229540 | 0.77 | ALDH1A1 (0.42) | ASPH | |
| SCHEMBL503280 | 0.75 | IDO1 (0.43) | IDO1 | |
| SCHEMBL13245781 | 0.75 | PDK2 (0.36) | ASPH | |
| SCHEMBL12946093 | 0.75 | HPGD (0.32) | ASPHIDO1 | |
| SCHEMBL909216 | 0.75 | PIK3CD (0.49) | ASPHIDO1 | |
| SCHEMBL2146577 | 0.75 | CYP11B1 (0.38) | ASPHIDO1 | |
| SCHEMBL30636340 | 0.75 | PIK3CD (0.49) | ASPHIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-09-05 | — | — | US | disclosed |
| EP-4385574-A2 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | The Regents of the University of California (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11771687-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-03 | — | — | US | disclosed |
| EP-2004181-B3 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | UNIV CALIFORNIA (US) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | AR, HRAS, NR5A1 | ASPH 439/4885IDO1 2968/4885 |
| US-11771687-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | AR, HRAS, NR5A1 | ASPH 439/4885IDO1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.